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AIM
The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg–1 twice
daily (b.i.d.) to 2 mg kg–1 three times daily (t.i.d.) in children with pulmonary arterial hypertension (PAH) (from ≥3 months
to <12 years of age) would increase exposure.
METHODS
An open-label, prospective, randomized, multicentre, multiple-dose, phase III study was conducted. Patients (n = 64) were
randomized 1:1 to receive oral doses of bosentan of 2 mg kg–1 b.i.d. or t.i.d. The main pharmacokinetic endpoint was the daily
exposure to bosentan over 24 h corrected to the 2 mg kg–1 dose (AUC0–24C). The maximum plasma concentration corrected to
the 2 mg kg–1 dose (CmaxC), the time to reach the maximum plasma concentration (tmax) and safety endpoints were also assessed.
RESULTS
The geometric mean [95% conﬁdence interval (CI)] for AUC0–24C was 8535 h.ng ml
–1 (6936, 10 504) and 7275 h.ng ml–1 (5468,
9679) for 2 mg kg–1 b.i.d. and t.i.d., respectively [geometric mean ratio (95% CI) 0.85 (0.61, 1.20)]. The geometric mean (95%
CI) for CmaxC was 743 ngml
–1 (573, 963) and 528 ngml–1 (386, 722) for 2 mg kg–1 b.i.d. and t.i.d., respectively [geometric mean
ratio (95% CI) 0.71 (0.48, 1.05)]. The median (range) for tmax was 3.0 h (0.0–7.5) and 3.0 h (1.0–8.0) for 2 mg kg
–1 b.i.d. and
t.i.d., respectively. The proportions of patients who experienced ≥1 adverse event were similar in the b.i.d. (66.7%) and t.i.d.
(67.7%) groups.
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CONCLUSIONS
There appeared to be no clinically relevant difference in exposure to bosentan, or in safety, when increasing the frequency of
bosentan dosing from b.i.d. to t.i.d. Therefore, the present study provides no indication that the dosing recommendation should
be changed, and 2 mg kg–1 b.i.d. remains the recommended dosing regimen for bosentan in paediatric PAH patients.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• In paediatric pulmonary arterial hypertension patients:
◯ Bosentan exposure following 2 mg kg–1 twice-daily (b.i.d.) dosing is approximately half that observed in adults with
bosentan 125 mg b.i.d., whereas the efﬁcacy seems to be similar.
◯ Increasing the dose to 4 mg kg–1 b.i.d. does not increase exposure.
◯ Bosentan has been shown to be well tolerated at both doses.
WHAT THIS STUDY ADDS
• The present study used a new bosentan dosing regimen, 2 mg kg–1 t.i.d., to investigate whether exposure could be
increased in paediatric pulmonary arterial hypertension patients.
• The study also provided the ﬁrst information on bosentan safety and pharmacokinetics in patients below 2 years of age.
Tables of Links
TARGETS
G protein-coupled receptors
ETA receptor
ETB receptor
LIGANDS
Bosentan
These Tables list key protein targets and ligands in this article that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1], and are permanently archived in the Concise Guide to
PHARMACOLOGY 2015/16 [2].
Introduction
Pulmonary arterial hypertension (PAH) is a progressive
disease caused by proliferation and remodelling of the
pulmonary vasculature, resulting in right ventricular failure
and death [3, 4]. With regard to deﬁnition,
pathophysiology, symptoms and response to PAH-speciﬁc
therapies, there are important similarities between PAH in
children and in adults [5].
The use of PAH-speciﬁc therapies in paediatric patients is
generally based on evidence from randomized controlled
trials in adults. Data to support their use in children are
limited mainly to uncontrolled studies and clinical
experience [6–10]. There is also a general lack of information
with regard to safety and optimal dosing strategies in
paediatric PAH patients [7]. The European Medicines Agency
(EMA) guidelines for the conduct of paediatric PAH studies
require comprehensive pharmacokinetic (PK) data and long-
term safety data to be provided [7]. Therefore, there is a clear
need for long-term trials in paediatric PAH, with an emphasis
on the collection of both PK and safety data, as it is difﬁcult to
extrapolate from adult studies [11].
Bosentan is an oral dual endothelin receptor antagonist
(ERA) that is approved for the treatment of PAH [12]. Studies
have been conducted to support the effectiveness of bosentan
using haemodynamic variables in adult [13–16] and
paediatric patients [9]. Similar haemodynamic
improvements were shown in both populations after
administration of the ﬁlm-coated (adult) tablet formulation
[9, 13–16]. In the Bosentan Randomised Trial of Endothelin
Antagonist Therapy-3 (BREATHE-3), clinically relevant
improvements from baseline in the exploratory endpoints
mean pulmonary artery pressure (mPAP) and pulmonary
vascular resistance (PVR) index were observed after 12 weeks
of treatment, even though bosentan plasma concentrations
in paediatric patients did not reach those previously observed
in adult PAH patients (approximately 50% lower) [8, 9, 17].
Several observational studies have also indicated that
bosentan may be effective in the treatment of paediatric
PAH [18–21]. One study demonstrated that bosentan
improved or maintained World Health Organization
functional class (WHO FC) in 90% of patients over a median
treatment duration of 14 months; decreases in mPAP and
PVR were also observed [18].
In the Paediatric FormUlation of bosenTan in pUlmonary
arterial hypeRtEnsion (FUTURE-1) open-label, uncontrolled
study, an oral, dispersible paediatric formulation of bosentan
with a quadrisecting score line was investigated, which
provided more ﬂexible dosing and increased acceptance for
paediatric patients [8]. A systemic exposure plateau was
observed at a dose of 2 mg kg–1 twice daily (b.i.d.) in
paediatric patients, with administration of bosentan at
4 mg kg–1 b.i.d. not resulting in higher plasma con-
centrations. As a result, the level of exposure to bosentan
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observed in adult PAH patients could not be reached in
paediatric patients with b.i.d. dosing [8]. Nevertheless,
observations in bosentan-naïve patients suggested a
beneﬁcial therapeutic effect following initiation of bosentan
[8]. FUTURE-2, an open-label, uncontrolled extension of
FUTURE-1 in which patients were allowed additional
PAH-speciﬁc therapy in the case of PAH worsening,
demonstrated an improvement in different efﬁcacy
parameters over long-term treatment [6]. The paediatric
formulation of bosentan was well-tolerated in both FUTURE
studies [6, 8]. Bosentan 32 mg dispersible tablets were
approved in the European Union, based on the results of
the paediatric clinical development programme that
included the studies listed above.
FUTURE-3 aimed to complement the understanding of
bosentan dosing in paediatric patients by investigating
whether increasing the dosing frequency from b.i.d. to three
times daily (t.i.d.) would result in increased daily systemic
exposure. The main objective of FUTURE-3 was to investigate
the PK of the paediatric formulation of bosentan at doses of
2 mg kg–1 b.i.d. and t.i.d. in children with PAH from
≥3 months to <2 years of age and from 2 years to <12 years
of age. Other main objectives of the study were to evaluate
the tolerability and safety of bosentan in children with PAH.
Methods
Study design
FUTURE-3 was an open-label, prospective, randomized,
multicentre, multiple-dose (two dose regimens), phase III
study in a paediatric population of PAH patients
(clinicaltrials.gov identiﬁer: NCT01223352). It was
predominantly designed as a PK study, and patients were
enrolled in 30 centres in Europe, North America, Latin
America, Australia, Asia and Africa.
FUTURE-3 consisted of a screening period (maximum
4 weeks), followed by a 24-week treatment period and a
7-day adverse event (AE) follow-up period. Patients were
randomized 1:1 to receive oral doses of bosentan of 2 mg
kg–1 b.i.d. (4 mg kg–1 total daily) or t.i.d. (6 mg kg–1 total
daily), stratiﬁed for baseline PAH-speciﬁc treatment
[treatment-naïve, bosentan, prostanoid, phosphodiesterase
type-5 (PDE-5) inhibitor or combinations thereof]. Patients
were randomized according to a randomization code
generated using Parexel® Informatics, Waltham, MA, USA.
Randomized treatment assignment was centralized via an
interactive voice/web response system in order to avoid
investigator bias in the allocation of treatment. Patients
who prematurely discontinued study treatment had to
complete an end-of-study (EOS) assessment. Patients
completing the study had the option of participation in a
1-year follow-up extension study. Those patients who did
not enter the 1-year follow-up extension had a 60-day
post-treatment follow-up of serious adverse events (SAEs)
and deaths.
Patients
The study population includedmale and female PAH patients
(≥3 months to <12 years of age) with idiopathic PAH (IPAH),
heritable PAH (HPAH) or associated PAH (APAH) persisting
after complete repair of a congenital heart defect, or PAH–
congenital heart disease (CHD) associated with systemic-to-
pulmonary shunts or Eisenmenger syndrome. Patients with
small defects and co-incidental APAH–CHD were also
permitted to enrol in the study. Patients were in WHO FC I-
III and diagnosed by right heart catheterization (RHC).
Baseline PAH therapy (calcium channel blocker, bosentan,
PDE-5 inhibitor, prostanoid), if present, had to be stable for
at least 3 months prior to screening. Exclusion criteria
included aspartate transaminase (AST) or alanine
aminotransferase (ALT) levels >1.5 times the upper limit of
normal range, moderate to severe hepatic impairment and
haemoglobin and/or haematocrit levels <75% of the lower
limit of normal range. Patients who required additional or
an increased dose of PAH-speciﬁc therapy had to discontinue
the study, with the option of joining the 1-year follow-up
extension study.
The protocol was approved by the Independent Ethics
Committee or Institutional Review Board at each
participating centre (Table S1) and the study was performed
in accordance with the principles of the Declaration of
Helsinki and within the regulations for each country. Written
informed consent was obtained from every child’s parents or
legal representatives (and assent was obtained from each
child if applicable) prior to any study procedure.
Outcome measures
The main PK endpoint was deﬁned as the daily exposure to
bosentan – i.e., the area under the concentration–time curve
(AUC) over a period of 24 h corrected to the 2 mg kg–1 target
dose (AUC0–24C), for b.i.d. or t.i.d. dosing (refer to PK and
statistical analyses section for details). Dose-corrected values
were used as the smallest dose unit was 8 mg (a quarter of a
tablet), so it was not possible to achieve the exact target dose
in all patients.
Other PK endpoints were the maximum plasma
concentration corrected to the 2 mg kg–1 dose (CmaxC) of
bosentan, time to reach the maximum plasma concentration
(tmax) of bosentan, and metabolite to parent AUC0–24C ratio
for the metabolites Ro 47–8634, Ro 48–5033, and Ro 64–
1056. The PK of the three metabolites was assessed in order
to understand whether a potential difference in exposure to
bosentan could be explained by the activity of the
cytochrome P450 (CYP)3A4 and/or CYP2C9 enzymes
responsible for the formation of these metabolites. Safety
endpoints included occurrence of treatment-emergent AEs,
SAEs, AEs leading to treatment discontinuation, death,
laboratory abnormalities, change from baseline in vital signs
and 12-lead electrocardiogram (ECG), and growth.
Trial procedures and analytical methods
Patient characteristics and demographic data were collected
at baseline. PK assessments were performed at week 4, after
at least 2 weeks of stable study treatment. Blood samples were
collected into ethylene diamine tetra-acetic acid-containing
tubes by venepuncture or from an indwelling catheter in an
arm vein. For the 2 mg kg–1 b.i.d. dosing regimen, samples
were collected immediately before administration of the
study medication dose (predose), and at 0.5, 1, 3, 7.5 and
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12 h postdose. For the 2 mg kg–1 t.i.d. dosing regimen,
samples were collected predose and at 0.5, 1, 3, 5 and 8 h
postdose. Concentrations of bosentan and its metabolites in
plasma were determined as previously described [22] or by
using liquid chromatography–tandem-mass spectrometry
following protein precipitation with methanol. The lower
limit of quantiﬁcation for bosentan varied between 1.00 ng
ml–1 and 2.00 ng ml–1, and for Ro 47–8634, Ro 48–5033 and
Ro 64–1056 it was 2.00 ng ml–1. The day-to-day precision
for both methods varied between 1.2% and 15.1% for
bosentan and its metabolites, and accuracy varied between
85.1% and 112.9%. Dried blood spot samples were also
collected and compared with the plasma samples [23]. Safety
and tolerability were evaluated by monitoring safety
variables, including laboratory abnormalities, AEs, SAEs,
death, vital signs, 12-lead ECG and growth.
PK and statistical analyses
The sample size was based on the expectation that
recruitment of at least 64 patients would lead to at least 50
evaluable patients; for a sample size of 25 patients in each
dosing regimen, and assuming that the standard deviation
(SD) of the log-transformed data is 0.650 [8], an increased
daily exposure of at least 45% would be necessary to obtain
a 95% conﬁdence interval (CI) that does not include 1.00
(i.e., statistically signiﬁcant).
Analyses of PK parameters were performed for the overall
population and for age subgroups <2 years and ≥2 years.
Statistical analyses of PK parameters were performed on the
PK set, which included patients who received at least one
dose of study drug, and provided at least ﬁve of the six blood
samples (including the predose and the 8 h or 12 h postdose
samples) and who did not violate the protocol in a way that
might affect the evaluation of the main PK endpoint. The
PK parameters were determined using a noncompartmental
analysis using the Phoenix 64 6.3 software package (Certara
L.P., St Louis, MO, USA) on the basis of scheduled time points
if there was notmore than 5% deviation from the actual ones.
AUC0–24C was calculated as a multiple of the exposure over a
dosing interval (AUC) (3 × AUC and 2 × AUC for t.i.d. and
b.i.d., respectively). AUC0–24 and Cmax were corrected to the
target dose of 2 mg kg–1 bosentan (AUC0–24C and CmaxC) by
dividing these values by the actual dose received and
multiplying by 2. All AUC and Cmax values were assumed to
be log-normally distributed.
The ratios of geometric means of AUC0–24C and CmaxC of
bosentan were calculated [test treatment (t.i.d.) : reference
treatment (b.i.d.)] and a linear ﬁxed-effects model, with
dosing regimen as ﬁxed effect, was used to estimate the
95% CIs. Geometric mean ratios (90% CI) of the metabolite
to bosentan AUC0–24C values were also calculated. The
inﬂuence of baseline characteristics (WHO FC, body weight,
gender, and age at study entry) on AUC0–24C was assessed in
post hoc sensitivity analyses using the linear ﬁxed-effects
model to produce baseline covariate-adjusted geometric
mean ratios. One interim safety analysis was planned for
the study, to identify the need for any dose change. There
were no changes in the planned dosing due to this analysis.
Safety data were analysed descriptively for the all-treated
set, which included all randomized patients who received
at least one dose of study drug. AEs and SAEs were coded
using the Medical Dictionary for Regulatory Activities
(MedDRA) version 16.0. Upper respiratory tract infection
AEs were analysed based on Actelion internal MedDRA
queries (nasopharyngitis, inﬂuenza, laryngitis, pharyngitis,
tonsillitis, bacterial upper respiratory tract infection, viral
pharyngitis, and viral rhinitis). Statistical Analysis System
(SAS) software, version 9.3 (SAS Institute, Cary, NC, USA)
was used for all statistical analyses.
Results
Patient characteristics
In FUTURE-3, 64 patients were randomized to bosentan 2 mg
kg–1 b.i.d. (n = 33) or 2 mg kg–1 t.i.d. (n = 31) (Figure 1). Of the
randomized patients, 21 were <2 years old (10 treated with
2 mg kg–1 b.i.d. and 11 t.i.d.). All patients who were
randomized received the study treatment. The PK set
included 58 patients (90.6% of the all-randomized set).
Among all-randomized patients, demographic and baseline
characteristics were generally similar in the 2 mg kg–1 b.i.d.
and t.i.d. groups, although there was a smaller proportion
both of females and FC III patients in the 2 mg kg–1 t.i.d.
group compared with b.i.d. (female: 32.3% vs. 54.5%,
respectively; FC III: 19.4% vs. 36.4%, respectively) (Table 1).
The percentage of patients on background therapy was
consistent across dosing regimens, with 60.6% and 67.7% of
patients in the 2 mg kg–1 b.i.d. and t.i.d. groups, respectively,
on background therapy in the overall population. The
majority of patients were receiving either bosentan or a
PDE-5 inhibitor at baseline (Table 1). The mean duration of
bosentan treatment (weeks ± SD) was 23.6 ± 3.7 weeks in
the 2 mg kg–1 b.i.d. group and 23.3 ± 5.0 weeks in the 2 mg
kg–1 t.i.d. group.
PK parameters in the overall population
The PK parameters of bosentan for the 2 mg kg–1 b.i.d. and
t.i.d. dosing regimens are described in Table 2. In the overall
population, the main PK endpoint of AUC0–24C was lower
for 2 mg kg–1 t.i.d. [geometric mean (95% CI): 7275 h.ng
ml–1 (5468, 9679)] compared with 2 mg kg–1 b.i.d. [geometric
mean (95% CI): 8535 h.ng ml–1 (6936, 10 504)]; however,
there was high interindividual variability in AUC0–24C for
both dosing regimens (Figure S1). The geometric mean ratio
(95% CI) was 0.85 (0.61, 1.20) and as the CI between the
two dose groups included 1.00, no statistically signiﬁcant
difference could be demonstrated, suggesting that AUC0–24C
was comparable between the two regimens.
In the overall population, the geometric mean (95% CI)
for CmaxC of bosentan in patients who were dosed 2 mg kg
–1
t.i.d. was 29% lower than for patients who were dosed 2 mg
kg–1 b.i.d. [528 ng ml–1 (386, 722) and 743 ng ml–1 (573,
963), respectively]. However, as for AUC0–24C, the 95% CI
around the geometric mean ratio [0.71 (0.48, 1.05)] showed
high variability and included 1.00, indicating that CmaxC
was also comparable for both dosing regimens (Table 2).
The PK proﬁles of bosentan for both dosing regimens were
characterized by rapid absorption, with a median tmax of 3 h
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(range 0.0–7.5 and 1.0–8.0 for 2 mg kg–1 b.i.d. and t.i.d.,
respectively) (Figure 2, Table 2).
Post hoc sensitivity analyses were performed to explore the
inﬂuence of speciﬁc baseline covariates on AUC0–24C and
CmaxC between the two dosing regimens. After adjusting for
these covariates, the results were consistent with the
unadjusted analyses (Table 3).
Themetabolite to parent AUC0–24C ratios for the 2mg kg
–1
b.i.d. and t.i.d. dosing regimens were comparable (Table 4).
PK parameters by age group
Overall, PK parameters for b.i.d. and t.i.d. dosing were
comparable in both age groups, as indicated by the 95%
CI of the geometric mean of AUC0–24C and CmaxC, which
largely overlapped for both dosing regimens in both age
groups (Table 2). The median tmax was identical (3 h) for
patients ≥2 years for both dosing regimens. In patients
<2 years, the median tmax occurred later for t.i.d. dosing
(4 h) compared with b.i.d. dosing (3 h). The dosing
regimen had no effect on the metabolite to parent AUC0–
24C ratios of Ro 47–8634, Ro 48–5033, or Ro 64–1056 across
the age groups (Table 4). PK parameters of bosentan and
the metabolite to bosentan AUC0–24C ratio in patients
<2 years were consistent with those in patients ≥2 years
(Table 2, Table 4).
Safety and tolerability
In the overall population, the proportions of patients who
experienced ≥1 AE were similar in the b.i.d. (66.7%) and
t.i.d. (67.7%) groups (Table 5), with events denoting upper
respiratory tract infections being the most frequent and
occurring at a similar frequency in both groups (36.4%,
b.i.d.; 45.2%, t.i.d.; Table S2). The proportions of patients
with ≥1 AE in the b.i.d. and t.i.d. regimens were comparable
across age groups (Table 5). Overall, there was a slightly
higher proportion of SAEs in the t.i.d. dosing regimen
(19.4%) compared with b.i.d. (12.1%) (Table 5) and all SAEs
were assessed by the investigator as unrelated to study drug
administration. A total of three (4.7%) patients [two
patients (6.1%), b.i.d.; one patient (3.2%), t.i.d.]
permanently discontinued study treatment owing to AEs
that indicated a worsening of PAH, which in one case was
associated with bronchopneumonia and in another with
infection in the context of a congenital metabolic disease.
Figure 1
Patient disposition. *Patients who prematurely discontinued treatment were considered to have completed the study, per protocol, as they
provided a valid end-of-study assessment. †This patient did not provide postbaseline laboratory data. b.i.d., twice daily; PK, pharmacokinetic;
t.i.d., three times daily
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All AEs that led to study treatment discontinuation were
SAEs. Two patients (3.1%) died during the study [up to
60 days after study drug discontinuation; one patient
(3.0%), b.i.d.; one patient (3.2%), t.i.d.]. In general, changes
in laboratory variables were balanced between the b.i.d. and
t.i.d. groups. Elevations in ALT and/or AST >3 times the
upper limit of normal were reported for two patients
(3.1%), both of whom were in the t.i.d. group. In both
patients, the ALT/AST levels returned to normal levels,
following permanent discontinuation of bosentan treatment
in one case and treatment interruption in the other.
Decreases in haemoglobin values to <100 g l–1 were reported
in four patients (6.3%) [three patients (9.1%), b.i.d.; one
patient (3.2%), t.i.d.]. There were no relevant differences
between dosing regimens in the changes in vital signs, ECG
parameters or growth variables.
One patient with a congenital diaphragmatic hernia,
already on chronic bosentan therapy, did not meet the
aetiology inclusion criteria and was erroneously included in
the study. The condition of the patient was not expected to
affect the safety proﬁle and therefore the patient remained
in the study. Furthermore, no impact on the bosentan PK
was expected as a result of this condition. The patient was
on t.i.d. treatment and had an exposure of 6126 h.ng ml–1,
where the geometric mean (95% CI) of AUC0–24C in the
t.i.d. group was 7275 h.ng ml–1 (5468, 9679). This exposure
value would therefore not have affected a mean performed
with 27 patients in the PK set. For the age group analysis, this
Table 1
Summary of baseline demographics and characteristics by dosing regimen and age group
2 mg kg–1 b.i.d. 2 mg kg–1 t.i.d.
<2 years
n = 10
≥2 years
n = 23
Overall
n = 33
<2 years
n = 11
≥2 years
n = 20
Overall
n = 31
Gender, n (%)
Males 1 (10.0) 14 (60.9) 15 (45.5) 10 (90.9) 11 (55.0) 21 (67.7)
Females 9 (90.0) 9 (39.1) 18 (54.5) 1 (9.1) 9 (45.0) 10 (32.3)
Age (years), mean ± SD 1.3 ± 0.50 5.9 ± 3.07 4.5 ± 3.35 1.1 ± 0.51 7.5 ± 2.74 5.2 ± 3.81
Baseline PAH-speciﬁc treatment,
(consolidated stratiﬁcation
factor)a n (%)
Treatment-naïve 4 (40.0) 9 (39.1) 13 (39.4) 3 (27.3) 7 (35.0) 10 (32.3)
Bosentan 3 (30.0) 7 (30.4) 10 (30.3) 3 (27.3) 5 (25.0) 8 (25.8)
Prostanoid – – – – 1 (5.0) 1 (3.2)
PDE-5 inhibitor 3 (30.0) 7 (30.4) 10 (30.3) 5 (45.5) 7 (35.0) 12 (38.7)
Aetiology for PAH, n (%)b
IPAH 3 (30.0) 11 (47.8) 14 (42.4) 5 (45.5) 10 (52.6) 15 (50.0)
HPAH 1 (10.0) 1 (4.3) 2 (6.1) – – –
APAHc 1 (10.0) 10 (43.5) 11 (33.3) 5 (45.5) 8 (42.1) 13 (43.3)
PAH–CHD associated with
systemic-to-pulmonary shunts
or Eisenmenger syndrome
5 (50.0) 1 (4.3) 6 (18.2) 1 (9.1) 1 (5.3) 2 (6.7)
Time from ﬁrst observed/assumed
PAH symptomsd (dayse), mean ± SD
320.0 ± 218.98 796.4 ± 902.59 601.5 ± 735.71 283.0 ± 200.12 1058.5 ± 1053.42 800 ± 933.44
WHO FC, n (%)
I 2 (20.0) 6 (26.1) 8 (24.2) 3 (27.3) 5 (25.0) 8 (25.8)
II 3 (30.0) 10 (43.5) 13 (39.4) 4 (36.4) 13 (65.0) 17 (54.8)
III 5 (50.0) 7 (30.4) 12 (36.4) 4 (36.4) 2 (10.0) 6 (19.4)
aIn the case of a combination of PAH-speciﬁc medications, the following hierarchy was applied: bosentan > prostanoid > PDE-5 inhibitor
bOne patient from the ≥2-years t.i.d. dosing group had pulmonary hypertension associated with a congenital diaphragmatic hernia (nontargeted
aetiology), which was clariﬁed after randomization.
cPersisting after complete repair of a congenital heart defect (PAH had to be persistent for at least 6 months after surgery)
dTime from PAH symptoms excludes patients with an APAH aetiology
eCalculated in relation to the date of screening
All-randomized set. APAH, associated PAH; b.i.d., twice daily; HPAH, heritable PAH; IPAH, idiopathic PAH; PAH, pulmonary arterial hypertension;
PAH–CHD, PAH with congenital heart disease; PDE-5, phosphodiesterase-type 5; SD, standard deviation; t.i.d., three times daily; WHO FC, World
Health Organization functional class
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Figure 2
Arithmetic mean dose-corrected plasma concentration (± standard deviation) vs. time proﬁles of bosentan on a linear and semi-logarithmic scale.
Overall age group; PK set. b.i.d., twice daily; PK, pharmacokinetic; t.i.d., three times daily
Table 2
Summary of bosentan pharmacokinetic parameters by dosing regimen and age group
PK parameter Age group
2 mg kg–1 b.i.d. 2 mg kg–1 t.i.d.
Geometric mean ratio
(t.i.d./b.i.d.) (95% CI)n Geometric mean (95% CI) n Geometric mean (95% CI)
AUC0–24C (h*ng ml
–1) Overall 31 8535 (6936, 10 504) 27 7275 (5468, 9679) 0.85 (0.61, 1.20)
<2 years 9 7879 (4783, 12 979) 8 6756 (3761, 12 135) 0.86 (0.43, 1.72)
≥2 years 22 8820 (6939, 11 210) 19 7506 (5236, 10 759) 0.85 (0.57, 1.28)
CmaxC (ng ml
–1) Overall 31 743 (573, 963) 27 528 (386, 722) 0.71 (0.48, 1.05)
<2 years 9 622 (350, 1106) 8 487 (262, 905) 0.78 (0.36, 1.69)
≥2 years 22 799 (587, 1087) 19 546 (366, 814) 0.68 (0.42, 1.11)
tmax
a (h) Overall 31 3.0 (0.0, 7.5) 27 3.0 (1.0, 8.0)
<2 years 9 3.0 (0.0, 3.0) 8 4.0 (1.0, 8.0)
≥2 years 22 3.0 (0.0, 7.5) 19 3.0 (1.0, 8.0)
aMedian (range)
PK set. AUC0–24C, area under the concentration–time curve from 0 to 24 h; b.i.d., twice daily; CI, conﬁdence interval; CmaxC, maximum plasma
concentration; tmax, time to maximum plasma concentration; PK, pharmacokinetic; t.i.d., three times daily
Table 3
Geometric mean ratios between treatment groups for bosentan pharmacokinetic parameters, with and without adjustment for baseline covariates
Estimation method
Geometric mean ratio between treatment groups (t.i.d./b.i.d.) (95% CI)
AUC0–24C (h*ng ml
–1) CmaxC (ng ml
–1)
Unadjusted 0.85 (0.61, 1.20) 0.71 (0.48, 1.05)
Adjusted by weight at baseline 0.84 (0.59, 1.18) 0.70 (0.47, 1.05)
Adjusted by WHO FC at baseline 0.91 (0.66, 1.27) 0.74 (0.50, 1.11)
Adjusted by age at study entry 0.83 (0.59, 1.17) 0.70 (0.47, 1.05)
Adjusted by gender 0.89 (0.63, 1.26) 0.75 (0.50, 1.12)
Overall age group, PK set
n numbers are as follows: 2 mg kg–1 t.i.d.: (Overall: 27; <2 years: 8; ≥2 years: 19); 2 mg kg–1 b.i.d.: (Overall: 31; <2 years: 9; ≥2 years: 22)
AUC0–24C, area under the concentration time curve from 0 to 24 h; b.i.d., twice daily; CI, conﬁdence interval; CmaxC, maximum plasma
concentration; PK, pharmacokinetic; t.i.d., three times daily; WHO FC: World Health Organization functional class
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patient was part of the group ≥2 years. As for the overall
population, this exposure value would not have affected the
mean calculated for the 19 patients in the PK set. No speciﬁc
safety issues were noted for this patient.
Discussion
In the present study, the PK and safety proﬁle of an oral
paediatric formulation of bosentan were compared
following 2 mg kg–1 b.i.d. or t.i.d. dosing in paediatric
PAH patients. Although AUC0–24C and CmaxC differed
slightly between the b.i.d. and t.i.d. dosing regimens, given
the high variability of bosentan PK, these differences were
small and not considered clinically relevant, and statistical
analysis indicated that increasing the dosing frequency
from b.i.d. to t.i.d. did not alter these parameters in a
signiﬁcant manner. Baseline factors of age, gender, body
weight or FC did not inﬂuence the comparison of AUC0–
24C or CmaxC between the two dosing regimens. Other PK
endpoints (tmax for bosentan and metabolite to bosentan
exposure ratios) were also comparable between the dosing
regimens, with the latter indicating that the dosing regimen
did not inﬂuence the extent of metabolism of bosentan.
There was no effect of dosing regimen on the PK parameters
of bosentan or the metabolite to parent exposure ratios
across the age groups (<2 years and ≥2 years), and PK
parameters in patients <2 years were consistent with those
in patients ≥2 years.
Table 4
Summary of metabolite to bosentan AUC0–24C geometric mean ratios
Treatment
group n
Geometric mean ratio (metabolite/parent) (90% CI)
Ro 47–8634/bosentan Ro 48–5033/bosentan Ro 64–1056/bosentan
Overall
b.i.d. 31 0.02 (0.02, 0.03) 0.16 (0.14, 0.18) 0.12 (0.10, 0.15)
t.i.d. 27 0.03 (0.02, 0.03) 0.13 (0.12, 0.15) 0.10 (0.09, 0.12)
<2 years
b.i.d. 9 0.02 (0.02, 0.03) 0.17 (0.14, 0.19) 0.13 (0.09, 0.18)
t.i.d. 8 0.02 (0.02, 0.03) 0.15 (0.11, 0.21) 0.11 (0.08, 0.16)
≥2 years
b.i.d. 22 0.03 (0.02, 0.03) 0.16 (0.13, 0.18) 0.12 (0.09, 0.15)
t.i.d. 19 0.03 (0.02, 0.03) 0.13 (0.11, 0.14) 0.10 (0.08, 0.11)
PK set. AUC0–24C, area under the concentration time curve from 0 to 24 h; b.i.d., twice daily; CI, conﬁdence interval; PK, pharmacokinetic; t.i.d., three
times daily
Table 5
Summary of adverse events, serious adverse events and adverse events leading to discontinuationa
2 mg kg–1 b.i.d. 2 mg kg–1 t.i.d.
<2 years
n = 10
≥2 years
n = 23
Overall
n = 33
<2 years
n = 11
≥2 years
n = 20
Overall
n = 31
Treatment exposure, weeks, mean ± SD 22.8 ± 6.0 24.0 ± 2.2 23.6 ± 3.7 21.8 ± 8.3 24.1 ± 1.4 23.3 ± 5.0
Patients with ≥1 AE, n (%) 6 (60.0) 16 (69.6) 22 (66.7) 8 (72.7) 13 (65.0) 21 (67.7)
Total no. of AEs 19 43 62 31 61 92
Patients with ≥1 SAE, n (%) 2 (20.0) 2 (8.7) 4 (12.1) 4 (36.4) 2 (10.0) 6 (19.4)
Total no. of SAEs 5 3 8 8 2 10
Patients with ≥1 AE leading to treatment
discontinuation, n (%)
1 (10.0) 1 (4.3) 2 (6.1) 1 (9.1) – 1 (3.2)
No. of AEs leading to treatment
discontinuation
1 1 2 2b – 2b
aUp to end of treatment +7 days; all-treated set
bOne patient experienced two separate AEs leading to treatment discontinuation (PAH worsening and bronchopneumonia)
AE, adverse event; b.i.d., twice daily; PAH, pulmonary arterial hypertension; SAE: serious adverse event; SD, standard deviation; t.i.d., three times daily
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Previous studies have demonstrated that bosentan plasma
concentrations in paediatrics are lower than those in adult
PAH patients, both with the adult ﬁlm-coated [9] and the
paediatric dispersible formulation tablets [8]. FUTURE-1
showed that increasing the dose of bosentan above 2 mg kg–1
did not increase exposure in paediatric PAH patients in a
b.i.d. regimen [8]. Therefore, the t.i.d. dosing regimen was
explored in the present study. The data from FUTURE-3 show
that – across the paediatric age groups – dosing with bosentan
more frequently than twice daily is unlikely to result in
increased exposure. A small decrease in exposure was seen
with t.i.d. dosing, although this was not considered to be
clinically relevant and, overall, the exposure after both t.i.d.
and b.i.d. dosing was similar to that observed with bosentan
2 mg kg–1 or 4 mg kg–1 b.i.d. in previous paediatric studies
[8, 9]. The median tmax for both dosing regimens in the study
was also similar to values observed previously in healthy
adults [17, 24] and paediatric populations [8, 9]. The results
of the present study support those previously seen in
FUTURE-1, where it was suggested that paediatric PAH
patients reach a bosentan exposure plateau at a lower dose
than adults [8]. One possible explanation for this could be
the smaller intestinal surface area and/or different
absorption characteristics in paediatric patients [8]. In
addition, in BREATHE-3, paediatric patients experienced
auto-induction of the CYP3A4 and 2C9 enzymes following
bosentan administration, similarly to adults [9]. It is not
known if increasing the dosing frequency may have had
an impact on the level of auto-induction seen in paediatrics,
and whether this affected the exposure to bosentan after
t.i.d. dosing. In adult patients, it is usual practice for safety
reasons to initiate bosentan at 62.5 mg b.i.d. and increase
to the maintenance dose of 125 mg b.i.d. after 4 weeks
[12]. However, this is not required in paediatric patients as
children have a lower exposure to bosentan compared with
adults and therefore already have an adequate safety
margin. Thus, in the present study, no dose increase was
performed, in line with the current prescribing information
for bosentan in paediatric patients [12]. In previous studies,
2 mg kg–1 b.i.d. bosentan has been shown to be effective in
improving haemodynamics in adults [13–15] and children
[9], and its long-term safety proﬁle has been assessed [6].
The present study provided no indication that the dosing
recommendation should be changed, and 2 mg kg–1 b.i.d.
remains the recommended dosing regimen for bosentan in
paediatric PAH patients.
Bosentan induces CYP3A4 and CYP2C9; these isozymes
catalyse the formation of the three bosentan metabolites
[12]. PK parameters of bosentan and its metabolite to parent
exposure ratio in patients<2 years were consistent with those
in patients ≥2 years. These data indicate that the enzyme
activity levels are similar in both age groups. This is an
important ﬁnding as this was the ﬁrst paediatric study of
bosentan to investigate PK in a population <2 years of age.
Although ERAs, PDE-5 inhibitors and prostanoids are all used
for the treatment of paediatric PAH and have improved
outcomes [25], the evidence base for their use in paediatric
patients <2 years is limited [7–9, 25, 26].
The majority of AEs were those that would be expected
within a paediatric population (e.g. respiratory tract
infections) [6], or were consistent with the known safety
proﬁle of bosentan in paediatrics [8]. The safety proﬁle
showed no clinically relevant differences between t.i.d. or
b.i.d. dosing regimens. FUTURE-3 provided important safety
data for bosentan in this group of paediatric PAH patients
and there were no new safety risks identiﬁed in patients aged
3 months to <2 years.
Limitations of the study included a small sample size of
patients below 2 years, which reﬂects the challenges in
recruiting for paediatric PAH studies due to the rare and
heterogeneous nature of paediatric PAH [7, 10]. In
addition, no placebo or active comparator was used, which
may have been a limitation for the safety analysis of
bosentan. However, the use of placebo was not considered
appropriate due to the widespread use of bosentan and/or
other PAH-speciﬁc medications in the paediatric PAH
population. Although the target dose of bosentan was
2 mg kg–1, the smallest dose unit was 8 mg (a quarter of
a tablet). It was therefore not possible to achieve the exact
target dose in all patients. This imprecision could have
affected the PK parameters to a small extent, particularly
for children with low body weights. Dose-corrected values
were used during the analysis, to control for this
imprecision.
Overall, there appeared to be no difference in daily
exposure, and no clinically relevant differences in safety,
when increasing the frequency of bosentan dosing from
2 mg kg–1 b.i.d. to 2 mg kg–1 t.i.d. In addition, the PK of
bosentan in patients <2 years of age were consistent with
those in patients ≥2 years. Therefore, the present study
provided no indication that the dosing recommendation
should be changed, and it is concluded that 2 mg kg–1 b.i.d.
remains the recommended dosing regimen for bosentan in
paediatric PAH patients.
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